Analyst Price Target is $55.00
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cyclerion Therapeutics in the last 3 months. The average price target is $55.00, with a high forecast of $55.00 and a low forecast of $55.00. The average price target represents a ∞ upside from the last price of $0.00.
Current Consensus is
Moderate Buy
The current consensus among 2 investment analysts is to moderate buy stock in Cyclerion Therapeutics.
Cyclerion Therapeutics
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More
